Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khalil Zaman

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Revue Medicale Suisse|December 8, 2007
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]Lucien Perey, Khalil Zaman
Revue Medicale Suisse|June 14, 2013
[Endocrine therapy in breast cancer: efficacy and adverse events]Rahel Odermatt, Anita Wolfer, Khalil Zaman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone lossKhalil Zaman, Beat Thuerlimann, Stefan Aebi
Revue Medicale Suisse|July 6, 2017
[Hormone therapy in invasive breast cancer : update 2016]Jean-Philippe Zurcher, Athina Stravodimou, Khalil Zaman
Revue Medicale Suisse|June 25, 2010
[Cardiologic follow up of an oncologic patient]Danielle Zaugg Longchamp, Khalil Zaman, Nicole Aebischer
Breast (Edinburgh, Scotland)|March 15, 2011
Breast sarcomas: current and future perspectivesIoannis A Voutsadakis, Khalil Zaman, Serge Leyvraz
ISRN Oncology|July 10, 2014
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution SeriesAthina Stravodimou, Khalil Zaman, Ioannis A Voutsadakis
The Oncologist|June 5, 2012
Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic diseaseStefan Zimmermann, Khalil Zaman, Anita Wolfer, et al.
Revue Medicale Suisse|May 17, 2018
[Liquid biopsy, a new opportunity for personalized oncology]Christoforos Astaras, Ana Dolcan, Bettina Bisig, et al.
Revue Medicale Suisse|June 2, 2021
[New-onset diabetes and novel targeted therapies against cancer]Alessandro Zordan, Christophe Kosinski, Khalil Zaman, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Revue Medicale Suisse|December 8, 2007
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]Lucien Perey, Khalil Zaman
Revue Medicale Suisse|June 14, 2013
[Endocrine therapy in breast cancer: efficacy and adverse events]Rahel Odermatt, Anita Wolfer, Khalil Zaman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone lossKhalil Zaman, Beat Thuerlimann, Stefan Aebi
Revue Medicale Suisse|July 6, 2017
[Hormone therapy in invasive breast cancer : update 2016]Jean-Philippe Zurcher, Athina Stravodimou, Khalil Zaman
Revue Medicale Suisse|June 25, 2010
[Cardiologic follow up of an oncologic patient]Danielle Zaugg Longchamp, Khalil Zaman, Nicole Aebischer
Breast (Edinburgh, Scotland)|March 15, 2011
Breast sarcomas: current and future perspectivesIoannis A Voutsadakis, Khalil Zaman, Serge Leyvraz
ISRN Oncology|July 10, 2014
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution SeriesAthina Stravodimou, Khalil Zaman, Ioannis A Voutsadakis
The Oncologist|June 5, 2012
Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic diseaseStefan Zimmermann, Khalil Zaman, Anita Wolfer, et al.
Revue Medicale Suisse|May 17, 2018
[Liquid biopsy, a new opportunity for personalized oncology]Christoforos Astaras, Ana Dolcan, Bettina Bisig, et al.
Revue Medicale Suisse|June 2, 2021
[New-onset diabetes and novel targeted therapies against cancer]Alessandro Zordan, Christophe Kosinski, Khalil Zaman, et al.
Pageof 10